Outcomes of Post-Transplant Rh-GCSF and Decitabine Maintenance Therapy in Patients With High-Risk Myeloid Neoplasm.

Am J Hematol · 2025 · PMC12417765 · PMID 40728375

Europe PMC DOI

hedged sentence

0.0690

closest p · 1.4× alpha

0.0690

boldest claim

The sentences

a strong trendp = 0.069so close (0.05 < p ≤ 0.1)

56.9%, p = 0.022) (Figure 1a , S6a ) and a strong trend towards better RFS was also observed after evaluating maintenance therapy as a time‐dependent covariate (73.4% vs. 58.2%, p = 0.069) (Figure S6b ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.